Psychiatric Genomics is a genomics-based drug discovery company working to discover new gene expression patterns and genetic pathways involved in psychiatric disorders in order to discover new therapeutic targets and new therapeutics for these CNS conditions. Psychiatric Genomics, Inc. creates and develops innovative small molecule drugs to treat mental illness. Many of these diseases such as bipolar disorder, schizophrenia, depression, and autism can be attributed to genetic factors. Using human tissues the company identifies gene expression patterns associated with psychiatric diseases. These data are incorporated into Psychiatric Genomics' proprietary Multi-Parameter High Throughput ScreenSM method to rapidly discover unique therapeutic compounds.
